Articles

Find an Article

Filter articles

Applied Filters

Showing 91 to 100 of 316 results

LSIPR 50 2017: Mr Justice Richard Arnold

UK10-11-2017

Mr Justice Richard Arnold was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

LSIPR 50 2017: Judy Jarecki Black

US10-11-2017

Judy Jarecki Black was selected in the LSIPR 50 2017 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.

LSIPR 50 2017: Jörg Thomaier

Germany10-11-2017

Jörg Thomaier was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

LSIPR 50 2017: Mike Young

US10-11-2017

Mike Young was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

LSIPR 50 2017: Raj Panjabi

India09-11-2017

Raj Panjabi was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.

Counterfeit drugs: protecting lives and IP

Brazil, Mexico01-11-2017

Fake pharmaceuticals not only harm innovators, they can have tragic consequences, and require a robust response from the authorities. LSIPR assesses how officials, particularly in South America, are responding to the threat.

The PTAB’s biggest test yet

US01-11-2017

With the PTAB facing questions over its authority and even constitutionality, life sciences companies seem to be faring well, at least compared to other industries, as LSIPR finds out.

Patent extension in Canada: Making up for lost time

Canada01-11-2017

Following the signing of a historic trade agreement with the EU, Canada now has a system of patent term extension. LSIPR considers the impact for pharmaceutical patentees.

Raising the plausibility bar

EU26-10-2017David Carling and Richard Wells

Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.

Bridging the great divide

Brazil24-10-2017Samantha Salim and Kene Gallois

Samantha Salim and Kene Gallois of Daniel Legal & IP Strategy investigate how Brazil’s patent office and health regulatory agency are coping with the complicated examination of pharmaceutical patent applications.

Showing 91 to 100 of 316 results

LSIPR